Navigation Links
Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

- Presentation to Be Webcast Live on Company's Website -

TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that senior management will present at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-Astoria Hotel in New York City.

Paul J. Lytle, Peregrine's chief financial officer, will provide a review of recent corporate developments.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at http://www.peregrineinc.com.

For more information about this conference, please visit: http://ceo.bio.org/opencms/ceo/2008/index.jsp

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
2. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
3. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... Calif. (PRWEB) , ... August 11, 2017 , ... Algenist ... plant collagen-based formulation unlocking collagen like never before. , Collagen is the key ... firsts to market with Liquid Collagen™, which include: , ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... ... to help the agriculture industry reach its ideal customers with the right message. ... nation. , “As a Midwest company, we realize how crucial the agriculture industry ...
(Date:8/10/2017)... ... August 09, 2017 , ... The ... the clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived ... clinical studies. , Dr. Travis Antes, head of analytical development at Capricor ...
(Date:8/10/2017)... Bahama (PRWEB) , ... August 09, 2017 , ... Okyanos ... will take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September ... pre-registration is required. , With oversight from the Ministry of Health’s National Stem ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
Breaking Biology News(10 mins):